Novel transcript antisense to LBX2 (ENSG00000272183)

ENSG00000272183, labeled as "novel transcript, antisense to LBX2," is a non-coding RNA transcribed in the antisense direction relative to the LBX2 gene. Natural antisense transcripts (NATs) are endogenous RNA molecules that overlap complementary protein-coding or non-coding regions in the genome. These NATs are often poorly characterized, and their functions can include modulation of alternative splicing, regulation of chromatin structure, transcriptional interference, or RNA masking, although such mechanisms have mostly been described generically and not for this specific locus[1][3]. No direct evidence links ENSG00000272183 to a disease role, protein product, or therapeutic interventions. Its status as a "novel transcript" antisense to LBX2 further suggests this is an annotation without experimental validation or biological characterization, and it is not a druggable protein, receptor, enzyme, or classical therapeutic target[1][3].

Other names

Antisense to LBX2ENSG00000272183LBX2-AS (not widely established or validated)